Overcoming innate immune barriers that impede AAV gene therapy vectors
Open accessThe DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
The field of gene therapy has made considerable progress over the past several years. Adeno-associated virus (AAV) vectors have emerged as promising and attractive tools for in vivo gene therapy. Despite the recent clinical successes achieved with recombinant AAVs (rAAVs) for therapeutics, host immune responses against the vector and transgene product have been observed in numerous preclinical and clinical studies. These outcomes have hampered the advancement of AAV gene therapies, preventing them from becoming fully viable and safe medicines. The human immune system is multidimensional and complex. Both the innate and adaptive arms of the immune system seem to play a concerted role in the response against rAAVs. While most efforts have been focused on the role of adaptive immunity and developing ways to overcome it, the innate immune system has also been found to have a critical function. Innate immunity not only mediates the initial response to the vector, but also primes the adaptive immune system to launch a more deleterious attack against the foreign vector. This Review highlights what is known about innate immune responses against rAAVs and discusses potential strategies to circumvent these pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“further supported with the reports of complement-mediated TMA cases in subjects receiving high doses of systemic AAV (40, 41)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the goal of commonly used immunomodulation regimes was to inhibit T cell function and included mostly corticosteroids, sirolimus, tacrolimus, mycophenolate mofetil, or cyclosporine (40, 41).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, rAAV capsid-targeting TLR2, various DNA sensors, and complement activation may also play a role (22).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · cited 2×
“Figure 1, activated IRAKs lead to transcription of several proinflammatory cytokines, including TNF-α and IL-6 (35).”
BackgroundPattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895 · cited 1×
“These signals lead to the expression of host defense genes, like the MHC genes, proinflammatory cytokines, chemokines, and type I and III IFNs (31).”
BackgroundCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“TLRs that have been implicated in initiating inflammatory responses to viruses are TLR2 (glycoproteins and lipoproteins), TLR3 (dsRNA), TLR4 (glycoproteins and bacterial LPS), TLR7 (ssRNA), TLR8 (ssRNA), and TLR9 (unmethylated CpG [cytosine-phosphate-guanine] DNA) (39).”
BackgroundRegulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297 · cited 2×
“Secreted cytokines and chemokines are also critical for inducing effective adaptive and memory immune responses (33).”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233 · cited 4×
“TLR1, 2, 4, 5, 6, and 10 (glycoprotein-recognizing receptors) are commonly located on the cell surface, whereas TLR3, 7, 8, and 9 (nucleic acid–specific receptors) are generally found on the endosomal membrane (38).”
BackgroundInfluentialSTING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“Mice deficient in cGAS and STING are more susceptible to lethal herpes simplex virus 1 (HSV1) infection because of a decrease in type I IFN response (71, 72).”
BackgroundIKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
Self-citationAIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E., & Fitzgerald, K. A. (2009) · Nature · doi:10.1038/nature07725 · Cited by 2,627 · cited 14×
“Further studies are required to elucidate whether AAV infection activates the AIM2 inflammasome pathway.”
BackgroundInfluentialSelf-citationAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Self-citationSignaling to NF-κB by Toll-like receptors
Kawai, T., & Akira, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.002 · Cited by 2,388
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“In addition, the capsid can trigger a cytotoxic T lymphocyte–mediated (CTL-mediated) response that leads to the loss of transgene expression (11).”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620 · cited 4×
“Depending on the pathogenic context, the complement system cascade is initiated by three different pathways — classical, lectin, and alternative — all of which converge at the level of complement protein C3 and lead to the formation of the membrane attack complex (MAC; terminal pathway).”
BackgroundInfluentialTerminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586 · cited 1×
“It is approved for the treatment of rare disorders involving complement hyperactivation, particularly paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, and refractory generalized myasthenia gravis (161).”
BackgroundInnate Immune Pattern Recognition: A Cell Biological Perspective
Brubaker, S. W., Bonham, K. S., Zanoni, I., & Kagan, J. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112240 · Cited by 1,475 · cited 1×
“Transcriptionindependent cellular processes such as phagocytosis, autophagy, metabolism, cell death, and inflammasome/cytokine activation are also induced (32).”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
The ins and outs of MHC class II-mediated antigen processing and presentation
Roche, P. A., & Furuta, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3818 · Cited by 1,207 · cited 1×
“Capsid peptides are loaded onto MHC class II and presented to CD4+ T cells (Figure 3B) (6, 135, 136).”
BackgroundEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 2×
“The host immune response is one of the most critical roadblocks limiting effective and long-term transgene expression (3, 5).”
BackgroundPivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects
Li, X.-D., Wu, J., Gao, D., Wang, H., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1244040 · Cited by 1,113 · cited 1×
“Mice deficient in cGAS and STING are more susceptible to lethal herpes simplex virus 1 (HSV1) infection because of a decrease in type I IFN response (71, 72).”
BackgroundGao, P., Ascano, M., Wu, Y., Barchet, W., Gaffney, B. L., Zillinger, T., Serganov, A. A., Liu, Y., Jones, R. A., Hartmann, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.046 · Cited by 1,101
Structural basis of STING binding with and phosphorylation by TBK1
Zhang, C., Shang, G., Gui, X., Zhang, X., Bai, X.-C., & Chen, Z. J. (2019) · Nature · doi:10.1038/s41586-019-1000-2 · Cited by 1,095 · cited 3×
“Fortunately, gene therapy via direct CNS It dimerizes upon binding to DNA and triggers a cascade involving STING and TBK1 to induce the transcription of type I IFN genes and antiviral cytokines, such as TNF-α and IL-6 (70).”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“AAVs are found naturally in multiple vertebrate species, including humans and nonhuman primates (1).”
BackgroundSelf-citationThe complement system in regulation of adaptive immunity
Carroll, M. C. (2004) · Nature Immunology · doi:10.1038/ni1113 · Cited by 1,035 · cited 1×
“As discussed above, co-engagement of CR2 with the B cell antigen receptor enhances antibody production (111, 112).”
BackgroundKawai, T., Sato, S., Ishii, K. J., Coban, C., Hemmi, H., Yamamoto, M., Terai, K., Matsuda, M., Inoue, J.-I., Uematsu, S., et al. (2004) · Nature Immunology · doi:10.1038/ni1118 · Cited by 1,033 · cited 1×
“TLR7, 8, and 9 can also induce type I IFNs by employing the MyD88 signaling pathway (44).”
MethodSarma, J. V., & Ward, P. A. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1034-0 · Cited by 974
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 12×
“Preexisting neutralizing antibodies (NAbs) against the AAV capsids are found in a large portion of the human population as a result of natural AAV infection (7, 8).”
BackgroundInfluentialTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 2×
“Capsid peptides are loaded onto MHC class II and presented to CD4+ T cells (Figure 3B) (6, 135, 136).”
BackgroundGoubau, D., Deddouche, S., & Reis e Sousa, C. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.007 · Cited by 843 · cited 1×
“1172/JCI143780 like (NOD-like) receptors (NLRs), C-type lectin receptors (CLRs), absent in melanoma 2–like (AIM2-like) receptors (ALRs), and retinoic acid–inducible gene I–like (RIG-I–like) receptors (RLRs) (29).”
BackgroundHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 2×
“Preexisting neutralizing antibodies (NAbs) against the AAV capsids are found in a large portion of the human population as a result of natural AAV infection (7, 8).”
BackgroundSelf-citationDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“Structural modifications • Structural studies have proposed that NAb recognition sites are localized in specific areas of the AAV capsid (115).”
BackgroundGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696 · cited 1×
“• AAV-DJ was generated from 8 serotypes in primary human hepatocytes in the presence of pooled human intravenous immunoglobulin (IVIG) (120).”
MethodMechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines
Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000702 · Cited by 606
Jin, T., Perry, A., Jiang, J., Smith, P., Curry, J. A., Unterholzner, L., Jiang, Z., Horvath, G., Rathinam, V. A., Johnstone, R. W., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.02.014 · Cited by 574 · cited 3×
“Upon binding to viral DNA, IFI16 can move to the cytosol to activate the inflammasome pathway (74, 82, 83).”
BackgroundSelf-citationZhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Brown, B. D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C., & Naldini, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1372 · Cited by 556
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 1×
“1172/JCI143780 Notably, use of self-complementary AAV (scAAV) vectors was shown to increase vector potency by providing notably faster and stronger transgene expression, allowing for lower and possibly safer vector doses (52).”
BackgroundcGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders
Andreeva, L., Hiller, B., Kostrewa, D., Lässig, C., de Oliveira Mann, C. C., Jan Drexler, D., Maiser, A., Gaidt, M., Leonhardt, H., Hornung, V., et al. (2017) · Nature · doi:10.1038/nature23890 · Cited by 511
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Barbalat, R., Lau, L., Locksley, R. M., & Barton, G. M. (2009) · Nature Immunology · doi:10.1038/ni.1792 · Cited by 456
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441
Huang, L. S., Hong, Z., Wu, W., Xiong, S., Zhong, M., Gao, X., Rehman, J., & Malik, A. B. (2020) · Immunity · doi:10.1016/j.immuni.2020.02.002 · Cited by 435 · cited 1×
“Another possibility is that AAV infection stresses the cell to release mitochondrial DNA into the cytosol, which then activates the cytosolic DNA sensors (Figure 1) (79, 80).”
BackgroundRIG-I in RNA virus recognition
Kell, A. M., & Gale, M. (2015) · Virology · doi:10.1016/j.virol.2015.02.017 · Cited by 428 · cited 3×
“1172/JCI143780 sensors, RLRs play key roles in virus recognition (88, 89).”
BackgroundNathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421 · cited 1×
“IX vectors was used for hemophilia trials, but the conclusions were not definitive (148, 149).”
MethodDifferential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394 · cited 3×
“This activation was revealed to be dependent on Kupffer cells, the resident macrophages of the liver (27).”
BackgroundRegulation of Humoral Immunity by Complement
Carroll, M. C., & Isenman, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.002 · Cited by 387 · cited 1×
“Antigens coated with complement activation fragments, like C3dg, assist in initiating a powerful costimulatory signal by ligating the B cell receptor to complement receptor 2 (CR2) on B cells, thereby reducing the threshold of B cell receptor activation and increasing the amplitude of the antibody response (107).”
BackgroundThe DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury
Hu, B., Jin, C., Li, H.-B., Tong, J., Ouyang, X., Cetinbas, N. M., Zhu, S., Strowig, T., Lam, F. C., Zhao, C., et al. (2016) · Science · doi:10.1126/science.aaf7532 · Cited by 378 · cited 2×
“AIM2 is also found in the nucleus (85), but it is not known whether AIM2 can sense viral DNA in nuclei.”
BackgroundSelf-citationGray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377
Cytosolic RNA:DNA hybrids activate the cGAS –STING axis
Mankan, A. K., Schmidt, T., Chauhan, D., Goldeck, M., Höning, K., Gaidt, M., Kubarenko, A. V., Andreeva, L., Hopfner, K., & Hornung, V. (2014) · The EMBO Journal · doi:10.15252/embj.201488726 · Cited by 359
Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47.
Ahn, K., Meyer, T. H., Uebel, S., Sempé, P., Djaballah, H., Yang, Y., Peterson, P. A., Früh, K., & Tampé, R. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00689.x · Cited by 358
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358 · cited 3×
“Directed evolution • Directed evolution can be used to identify AAV variants with decreased sensitivity to NAbs by iterative rounds of mutational screening to evolve AAV variants under selection pressure (9).”
BackgroundMethodComprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design
Ogden, P. J., Kelsic, E. D., Sinai, S., & Church, G. M. (2019) · Science · doi:10.1126/science.aaw2900 · Cited by 356
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355 · cited 1×
“Moreover, because empty capsids are not immunologically inert, mutant empty capsids could be used to reduce the effects of undesired immune activation (129).”
BackgroundAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“A substantial portion of the human population develop anti-AAV NAbs against naturally circulating AAVs, which can be detected in children as young as 2 years of age (7, 8, 98, 99).”
BackgroundIFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes
Almine, J. F., O’Hare, C. A. J., Dunphy, G., Haga, I. R., Naik, R. J., Atrih, A., Connolly, D. J., Taylor, J., Kelsall, I. R., Bowie, A. G., et al. (2017) · Nature Communications · doi:10.1038/ncomms14392 · Cited by 340 · cited 1×
“IFI16 may cooperate with the cGAS/STING pathway in some contexts (64, 75).”
BackgroundOnasemnogene Abeparvovec: First Global Approval
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01162-5 · Cited by 337
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336 · cited 1×
“zooepidemicus), may provide complete, rapid, and transient NAb-free windows for AAV vector delivery to patients (127, 128).”
BackgroundZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · cited 2×
“Additional preclinical studies are also needed to better predict safer doses and biomarkers of toxicity, as well as the influence of parameters like empty capsid levels, impurities resulting from manufacturing methods, mice revealed that only pDCs were capable of producing type I IFNs in response to AAV, which in turn…”
BackgroundJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
cGAS is activated by DNA in a length‐dependent manner
Luecke, S., Holleufer, A., Christensen, M. H., Jønsson, K. L., Boni, G. A., Sørensen, L. K., Johannsen, M., Jakobsen, M. R., Hartmann, R., & Paludan, S. R. (2017) · EMBO reports · doi:10.15252/embr.201744017 · Cited by 308
Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299
Dangers Within: DAMP Responses to Damage and Cell Death in Kidney Disease
Rosin, D. L., & Okusa, M. D. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040430 · Cited by 284 · cited 1×
“PRRs also recognize endogenous damage-associated molecular patterns (DAMPs), which, when gone awry, disrupt homeostasis and cause autoimmune diseases (30).”
BackgroundIFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP
Jønsson, K. L., Laustsen, A., Krapp, C., Skipper, K. A., Thavachelvam, K., Hotter, D., Egedal, J. H., Kjolby, M., Mohammadi, P., Prabakaran, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14391 · Cited by 283 · cited 17×
“IFI16 may cooperate with the cGAS/STING pathway in some contexts (64, 75).”
BackgroundInfluentialLehner, P. J., Karttunen, J. T., Wilkinson, G. W. G., & Cresswell, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6904 · Cited by 283
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 1×
“This change resulted in a capsid that was not recognized by mAb A20 (antibody that binds AAV2 and AAV3 capsids) (117), leading to enhanced transduction of skeletal muscle (118).”
BackgroundcGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection
Orzalli, M. H., Broekema, N. M., Diner, B. A., Hancks, D. C., Elde, N. C., Cristea, I. M., & Knipe, D. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424637112 · Cited by 265 · cited 18×
“IFI16 may cooperate with the cGAS/STING pathway in some contexts (64, 75).”
BackgroundInfluentialMeliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Variation matters: TLR structure and species-specific pathogen recognition
Werling, D., Jann, O. C., Offord, V., Glass, E. J., & Coffey, T. J. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.12.001 · Cited by 262 · cited 1×
“Receptor engagement with PAMPs or DAMPs leads to the formation of M-shaped TLR dimers or multimers, which in turn causes the multimerization of cytoplasmic TIR domains that recruit downstream adaptors (41).”
BackgroundCpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · cited 4×
“Induction of type I IFNs through TLR9 and MyD88 signaling was shown to be transgene- and serotype-independent (48).”
BackgroundInfluentialIntracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251 · cited 1×
“One hypothesis is that proteasomal degradation of the capsid exposes the AAV genome (78).”
BackgroundMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246 · cited 3×
“The use of scAAV genomes was revealed to increase the innate immune response to the transgene compared with single-stranded vectors (53, 54).”
BackgroundSynthetic muscle promoters: activities exceeding naturally occurring regulatory sequences
Li, X., Eastman, E. M., Schwartz, R. J., & Draghia-Akli, R. (1999) · Nature Biotechnology · doi:10.1038/6981 · Cited by 245
An, J., Woodward, J. J., Sasaki, T., Minie, M., & Elkon, K. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402793 · Cited by 239
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234 · cited 2×
“Alternative strategies • Modifying the route of administration can bypass encountering NAbs in circulation (125).”
BackgroundSalva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232
Self-citationZhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232
Functional Significance of Factor H Binding to Neisseria meningitidis
Schneider, M. C., Exley, R. M., Chan, H., Feavers, I., Kang, Y.-H., Sim, R. B., & Tang, C. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7566 · Cited by 230 · cited 1×
“Many pathogens have evolved mechanisms to evade direct activation of the complement system by mimicking host surfaces, thereby recruiting FH (110).”
BackgroundLi, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225 · cited 3×
“Preexisting neutralizing antibodies (NAbs) against the AAV capsids are found in a large portion of the human population as a result of natural AAV infection (7, 8).”
BackgroundBasic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy
Balakrishnan, B., & Jayandharan, G. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140302193709 · Cited by 225 · cited 2×
“In the absence of helper viruses, AAV remains latent in the host cell as nonreplicating epichromosomal DNAs, or is integrated into the host cell genome (2).”
BackgroundRNA sensors of the innate immune system and their detection of pathogens
Chen, N., Xia, P., Li, S., Zhang, T., Wang, T. T., & Zhu, J. (2017) · IUBMB Life · doi:10.1002/iub.1625 · Cited by 225
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219
Master sensors of pathogenic RNA – RIG-I like receptors
Schlee, M. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.06.007 · Cited by 217 · cited 3×
“1172/JCI143780 sensors, RLRs play key roles in virus recognition (88, 89).”
BackgroundThe complement system as a potential therapeutic target in rheumatic disease
Trouw, L. A., Pickering, M. C., & Blom, A. M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.125 · Cited by 216 · cited 1×
“, FH or factor I), blocking antibodies, peptides, small-molecule inhibitors, aptamers, siRNAs, and antisense oligonucleotides, are being developed and have been attempted for the treatment of diseases like age-related macular degeneration, neuromyelitis optica, and PNH with mixed results (162).”
BackgroundTse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210 · cited 1×
“Modifying these regions may yield AAV mutants that have the ability to evade NAb recognition without affecting transduction efficiency or tissue tropism (116).”
BackgroundMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
Wilson, J. M., & Flotte, T. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.182 · Cited by 203 · cited 1×
“Thus, it is now more important than ever to understand the mechanisms of immune activation against AAV to improve the safety of these gene therapy approaches (17, 18, 25).”
BackgroundImproving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Kishimoto, T. K., Ferrari, J. D., LaMothe, R. A., Kolte, P. N., Griset, A. P., O'Neil, C., Chan, V., Browning, E., Chalishazar, A., Kuhlman, W., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.135 · Cited by 201
The SKIV2L RNA exosome limits activation of the RIG-I-like receptors
Eckard, S. C., Rice, G. I., Fabre, A., Badens, C., Gray, E. E., Hartley, J. L., Crow, Y. J., & Stetson, D. B. (2014) · Nature Immunology · doi:10.1038/ni.2948 · Cited by 199 · cited 3×
“Expression of factors like hepatic selenoprotein (94), RNA helicase SKIV2L (95), or the long noncoding RNA lncATV (96) is increased upon viral infection, leading to the suppression of RIG-I activation.”
BackgroundAppledorn, D. M., Patial, S., McBride, A., Godbehere, S., Van Rooijen, N., Parameswaran, N., & Amalfitano, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2134 · Cited by 198
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180 · cited 1×
“• Rituximab and rapamycin administration, along with serotype switching (154), has also been demonstrated to induce immune tolerance and allows repeated rAAV administrations (155–158).”
BackgroundNuclear interferon-inducible protein 16 promotes silencing of herpesviral and transfected DNA
Orzalli, M. H., Conwell, S. E., Berrios, C., DeCaprio, J. A., & Knipe, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316194110 · Cited by 180 · cited 2×
“IFI16 also silences viral gene expression by facilitating heterochromatinization of the viral genome in the nucleus (76).”
BackgroundInnate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178 · cited 1×
“TLRs are mostly found in immune cells, including DCs, macrophages, B cells, and some T cells, but are also found in some nonimmune cells, such as fibroblasts and epithelial cells (40).”
BackgroundThe complement system in B cell regulation
CARROLL, M. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.03.017 · Cited by 177 · cited 1×
“As discussed above, co-engagement of CR2 with the B cell antigen receptor enhances antibody production (111, 112).”
BackgroundComplement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01990-07 · Cited by 177 · cited 6×
“Neutralizing antibody reduction • Since complement activation by AAVs takes place via the classical pathway and is triggered by antibody binding, approaches to reduce NAbs should also mitigate complement activation (109).”
BackgroundInfluentialKotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169
Chicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167 · cited 1×
“The technique has been used for successful and sustained gene transfer in NHPs and humans (122, 123).”
MethodXie, J., Xie, Q., Zhang, H., Ameres, S. L., Hung, J.-H., Su, Q., He, R., Mu, X., Seher Ahmed, S., Park, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.279 · Cited by 166
Self-citationDNA sensor cGAS-mediated immune recognition
Xia, P., Wang, S., Gao, P., Gao, G., & Fan, Z. (2016) · Protein & Cell · doi:10.1007/s13238-016-0320-3 · Cited by 164 · cited 1×
“Detection of rAAV genomes by cytosolic DNA sensors Several cytosolic DNA sensors are known to detect viral DNA (62), including cGAS (63), IFN-inducible protein 16 (IFI16) (64), and AIM2 (65) (summarized in Figure 1).”
BackgroundSelf-citationQiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X. (2011) · Gene Therapy · doi:10.1038/gt.2010.157 · Cited by 163
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162 · cited 6×
“However, these regulatory cassettes have been found to have leaky expression in DCs (140, 141). miRNA-mediated detargeting • Inclusion of binding sites for cognate miRNAs that have high levels of expression in APCs into vectors leads to degradation of transgene transcripts as a consequence of host miRNAs and results i…”
BackgroundInfluentialPaulk, N. K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A. P., Haft, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.021 · Cited by 161 · cited 1×
“These mutants escape NAb recognition in human sera and can transduce human hepatocytes more efficiently than preexisting AAV serotypes (121).”
BackgroundBae, J. H., Jo, S., Kim, S. J., Lee, J. M., Jeong, J. H., Kang, J. S., Cho, N.-J., Kim, S. S., Lee, E. Y., & Moon, J.-S. (2019) · Cells · doi:10.3390/cells8040328 · Cited by 159 · cited 1×
“Another possibility is that AAV infection stresses the cell to release mitochondrial DNA into the cytosol, which then activates the cytosolic DNA sensors (Figure 1) (79, 80).”
BackgroundRumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.018 · Cited by 154 · cited 1×
“Vector manufacturing and purification methods, a relatively unattributed factor, could also be a contributor to adverse effects (25, 26).”
BackgroundThe Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150 · cited 1×
“Two AAV-based drugs (Luxturna and Zolgensma) were recently approved by the FDA, and several clinical trials using AAV-based therapies are in progress (144, 145).”
MethodAAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye
Reichel, F. F., Dauletbekov, D. L., Klein, R., Peters, T., Ochakovski, G. A., Seitz, I. P., Wilhelm, B., Ueffing, M., Biel, M., Wissinger, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.018 · Cited by 145 · cited 1×
“Similarly, RIG-I and MDA5 were also found to be upregulated in the primate retina after long-term AAV transduction (93).”
BackgroundA comprehensive review of immunosuppression used for liver transplantation
Mukherjee, S., & Mukherjee, U. (2009) · Journal of Transplantation · doi:10.1155/2009/701464 · Cited by 140
Haberman, R. P., McCown, T. J., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8732-8739.2000 · Cited by 139 · cited 2×
“The AAV ITR has inherent promoter activity (90, 91).”
BackgroundMingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138 · cited 1×
“A substantial portion of the human population develop anti-AAV NAbs against naturally circulating AAVs, which can be detected in children as young as 2 years of age (7, 8, 98, 99).”
BackgroundRescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M., & Asokan, A. (2020) · JCI Insight · doi:10.1172/jci.insight.139881 · Cited by 137
Innate Sensing of DNA Virus Genomes
Ma, Z., Ni, G., & Damania, B. (2018) · Annual Review of Virology · doi:10.1146/annurev-virology-092917-043244 · Cited by 136 · cited 8×
“Upon binding DNA, cGAS promotes cGAMP synthesis, which activates the STING/IRF3 pathway and upregulates type I IFNs (146).”
BackgroundInfluentialRogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131 · cited 4×
“However, inactivation of Kupffer cells and macrophages by the macrophage inhibitor GdCl3 did not affect the response (131).”
BackgroundResultInfluentialMeliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127 · cited 1×
“IX expression ~10-fold, along with a corresponding increase in transduction efficiency (126).”
BackgroundMonahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125 · cited 1×
“Proteasome inhibitors • The use of proteasome inhibitors, which reduce ubiquitination to avoid proteasome-mediated degradation, reduces the presentation of capsid peptide fragments on MHC class I molecules and enhances in vitro and in vivo transduction (163, 164).”
BackgroundHerpes Simplex Virus Type 2 ICP47 Inhibits Human TAP but Not Mouse TAP
Tomazin, R., van Schoot, N. E. G., Goldsmith, K., Jugovic, P., Sempé, P., Früh, K., & Johnson, D. C. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2560-2563.1998 · Cited by 124
Adeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
Quigley, M., Martinez, J., Huang, X., & Yang, Y. (2009) · Blood · doi:10.1182/blood-2008-03-148809 · Cited by 121
Shao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119 · cited 14×
“Induction of type I IFNs through TLR9 and MyD88 signaling was shown to be transgene- and serotype-independent (48).”
BackgroundInfluentialFinn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115 · cited 1×
“Proteasome inhibitors • The use of proteasome inhibitors, which reduce ubiquitination to avoid proteasome-mediated degradation, reduces the presentation of capsid peptide fragments on MHC class I molecules and enhances in vitro and in vivo transduction (163, 164).”
BackgroundKaminski, J. J., Schattgen, S. A., Tzeng, T.-C., Bode, C., Klinman, D. M., & Fitzgerald, K. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300530 · Cited by 112 · cited 2×
“• The ability of TTAGGG motifs to inhibit cGAS and AIM2 inflammasome activation has also been documented (86, 87).”
BackgroundSelf-citationSteinhagen, F., Zillinger, T., Peukert, K., Fox, M., Thudium, M., Barchet, W., Putensen, C., Klinman, D., Latz, E., & Bode, C. (2018) · European Journal of Immunology · doi:10.1002/eji.201747338 · Cited by 112 · cited 2×
“• The ability of TTAGGG motifs to inhibit cGAS and AIM2 inflammasome activation has also been documented (86, 87).”
BackgroundPerez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020) · Brain Sciences · doi:10.3390/brainsci10020119 · Cited by 112
Sun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., & Koeberl, D. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.012 · Cited by 111
Cytomegaloviral control of MHC class I function in the mouse
Hengel, H., Reusch, U., Gutermann, A., Ziegler, H., Jonjic, S., Lucin, P., & Koszinowski, U. H. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01291.x · Cited by 109
Hordeaux, J., Hinderer, C., Goode, T., Katz, N., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.003 · Cited by 105
Dell'Oste, V., Gatti, D., Gugliesi, F., De Andrea, M., Bawadekar, M., Lo Cigno, I., Biolatti, M., Vallino, M., Marschall, M., Gariglio, M., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00384-14 · Cited by 102 · cited 1×
“Upon binding to viral DNA, IFI16 can move to the cytosol to activate the inflammasome pathway (74, 82, 83).”
BackgroundCapsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100 · cited 4×
“• AAV-specific plasmapheresis column was used to selectively and effectively deplete anti-AAV NAbs without affecting the total immunoglobulin pool from the plasma in NHPs (124).”
MethodInfluentialCorti, M., Cleaver, B., Clément, N., Conlon, T. J., Faris, K. J., Wang, G., Benson, J., Tarantal, A. F., Fuller, D., Herzog, R. W., et al. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.068 · Cited by 97
Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96 · cited 1×
“This change resulted in a capsid that was not recognized by mAb A20 (antibody that binds AAV2 and AAV3 capsids) (117), leading to enhanced transduction of skeletal muscle (118).”
BackgroundSystemic protein delivery by muscle-gene transfer is limited by a local immune response
Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., & Herzog, R. W. (2005) · Blood · doi:10.1182/blood-2004-03-0848 · Cited by 94 · cited 2×
“However, these regulatory cassettes have been found to have leaky expression in DCs (140, 141).”
BackgroundInnate Immune Recognition of Viruses and Viral Vectors
Huang, X., & Yang, Y. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.141 · Cited by 92
Gabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 90
The innate immune sensor IFI16 recognizes foreign DNA in the nucleus by scanning along the duplex
Stratmann, S. A., Morrone, S. R., van Oijen, A. M., & Sohn, J. (2015) · eLife · doi:10.7554/elife.11721 · Cited by 88 · cited 1×
“IFI16 can shuttle between the nucleus and cytoplasm and recognizes viral DNA in the nucleus by scanning along DNA duplexes (Figure 1) (81).”
BackgroundRogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85 · cited 3×
“This increase was also attributed to an amplified activation of the TLR9/MyD88 pathway (34).”
BackgroundHordeaux, J., Hinderer, C., Goode, T., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.004 · Cited by 81
Complement modulation of T cell immune responses during homeostasis and disease
Clarke, E. V., & Tenner, A. J. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr0214-109r · Cited by 80 · cited 1×
“1172/JCI143780 taining T cell viability, proliferation, and differentiation as illustrated in Figure 2 (108).”
BackgroundCodon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.026 · Cited by 80
Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.
Hensley, S. E., Cun, A. S., Giles-Davis, W., Li, Y., Xiang, Z., Lasaro, M. O., Williams, B. R. G., Silverman, R. H., & Ertl, H. C. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300024 · Cited by 78
The nucleic acid‐sensing inflammasomes
Xiao, T. S. (2015) · Immunological Reviews · doi:10.1111/imr.12281 · Cited by 74 · cited 3×
“Upon binding DNA, AIM2 and IFI16 form the inflammasome and promote maturation of IL-1β and IL-18 (82).”
BackgroundMimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A., Ohmori, T., Madoiwa, S., Ono, F., Ozawa, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.258 · Cited by 74 · cited 12×
“Preexisting neutralizing antibodies (NAbs) against the AAV capsids are found in a large portion of the human population as a result of natural AAV infection (7, 8).”
BackgroundInfluentialWang, D., Li, S., Gessler, D. J., Xie, J., Zhong, L., Li, J., Tran, K., Van Vliet, K., Ren, L., Su, Q., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.004 · Cited by 73
Self-citationQiu, J., Nayak, R., Tullis, G. E., & Pintel, D. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12435-12447.2002 · Cited by 72 · cited 1×
“The AAV ITR has inherent promoter activity (90, 91).”
BackgroundMajowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J., Konstantinova, P., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 71
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage
MOREUIL, C. D., Alavi, Z., & Pasquier, É. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14131 · Cited by 71
McIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70 · cited 1×
“Capsid peptides are loaded onto MHC class II and presented to CD4+ T cells (Figure 3B) (6, 135, 136).”
BackgroundPetry, H., Brooks, A. R., Orme, A. E., Wang, P., Liu, P., Xie, J., Kretschmer, P. J., Qian, H. S., Hermiston, T. W., & Harkins, R. N. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303037 · Cited by 68 · cited 1×
“In addition, cellular immune responses against the rAAV capsid and/ or transgene can trigger a strong humoral immune response and elicit NAbs that prevent successful vector readministration (10).”
BackgroundThe interferon-inducible DNA-sensor protein IFI16: a key player in the antiviral response.
Dell’Oste, V., Gatti, D., Ag, G., Gariglio, M., Landolfo, S., & Andrea, M. D. (2015) · PubMed · Cited by 68
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67
Wu, T., Töpfer, K., Lin, S.-W., Li, H., Bian, A., Zhou, X. Y., High, K. A., & Ertl, H. C. (2012) · Molecular Therapy · doi:10.1038/mt.2011.280 · Cited by 66 · cited 1×
“The use of scAAV genomes was revealed to increase the innate immune response to the transgene compared with single-stranded vectors (53, 54).”
BackgroundBoisgerault, F., Gross, D.-A., Ferrand, M., Poupiot, J., Darocha, S., Richard, I., & Galy, A. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.208 · Cited by 63 · cited 2×
“However, these regulatory cassettes have been found to have leaky expression in DCs (140, 141).”
BackgroundAdeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61 · cited 7×
“However, these regulatory cassettes have been found to have leaky expression in DCs (140, 141). miRNA-mediated detargeting • Inclusion of binding sites for cognate miRNAs that have high levels of expression in APCs into vectors leads to degradation of transgene transcripts as a consequence of host miRNAs and results i…”
BackgroundInfluentialMyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59 · cited 3×
“Antibody production against AAV capsids has also been observed (59).”
BackgroundRevisiting the “New” Inflammatory Toxicities of Adeno-Associated Virus Vectors
Flotte, T. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.29117.trf · Cited by 56 · cited 1×
“In the last few years, a series of studies have reported novel rAAV-related inflammatory toxicities in nonhuman primates (NHPs) and neonatal piglets (12).”
BackgroundSomanathan, S., Breous, E., Bell, P., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.40 · Cited by 54 · cited 1×
“Innate immunity against rAAVs is remarkably muted compared with that against adenoviruses, because rAAVs seem to lack the inflammatory cues to confer an effective CTL response against the transduced cell (27, 45).”
BackgroundXiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Self-citationChandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Fan, J., Cheng, M., Chi, X., Liu, X., & Yang, W. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01711 · Cited by 49 · cited 2×
“Expression of factors like hepatic selenoprotein (94), RNA helicase SKIV2L (95), or the long noncoding RNA lncATV (96) is increased upon viral infection, leading to the suppression of RIG-I activation.”
BackgroundCharge-Mediated Pyrin Oligomerization Nucleates Antiviral IFI16 Sensing of Herpesvirus DNA
Lum, K. K., Howard, T. R., Pan, C. X., & Cristea, I. M. (2019) · mBio · doi:10.1128/mbio.01428-19 · Cited by 46 · cited 2×
“Viral peptides • Several viruses, like HSVs and CMVs, produce small viral proteins that interfere with antigen presentation (177–180).”
BackgroundPetry, H., Orme, A., Liu, P., Bauzone, M., Gibson, H., Qian, H., Rubanyi, G. M., & Harkins, R. N. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.1088 · Cited by 43
Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.187 · Cited by 38 · cited 1×
“Thus, it is now more important than ever to understand the mechanisms of immune activation against AAV to improve the safety of these gene therapy approaches (17, 18, 25).”
BackgroundEfficient capsid antigen presentation from adeno-associated virus empty virions in vivo
Pei, X., Earley, L. F., He, Y., Chen, X., Hall, N. E., Samulski, R. J., & Li, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00844 · Cited by 35 · cited 1×
“The cross-presentation of AAV capsids on MHC class I is proteasome-dependent and is called the cytosolic pathway, which also leads to cross-priming of CD8+ T cells (Figure 3B) (133, 134).”
BackgroundButterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
Paulk, N. (2020) · Genetic Engineering & Biotechnology News · doi:10.1089/gen.40.09.04 · Cited by 35
Gonin, P., Arandel, L., Van Wittenberghe, L., Marais, T., Perez, N., & Danos, O. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.716 · Cited by 29
He, Y., Weinberg, M. S., Hirsch, M., Johnson, M. C., Tisch, R., Samulski, R. J., & Li, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.065 · Cited by 26
Murai, K., Honda, M., Shirasaki, T., Shimakami, T., Omura, H., Misu, H., Kita, Y., Takeshita, Y., Ishii, K., Takamura, T., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.015 · Cited by 26 · cited 2×
“Expression of factors like hepatic selenoprotein (94), RNA helicase SKIV2L (95), or the long noncoding RNA lncATV (96) is increased upon viral infection, leading to the suppression of RIG-I activation.”
BackgroundInhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17 · cited 1×
“• Fusion of VIPRs, like ICP47 with mini-dystrophin, decreased antigen presentation and blocked dystrophin-specific CTL response (181).”
BackgroundDhungel, B. P., Ramlogan‐Steel, C. A., & Steel, J. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-33801-4 · Cited by 15
TLR9 and Dendritic Cells Are Required for CD8+ T Cell Responses to the AAV Capsid
Rogers, G. L., & Herzog, R. W. (2014) · Blood · doi:10.1182/blood.v124.21.552.552 · Cited by 4
(2010) · Molecular Therapy · doi:10.1016/s1525-0016(16)37753-x · Cited by 3
Research works printed but not linked: 6
- Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy. Press release. Audentes Therapeutics. August 20, 2020. https://www.audentestx.com/press_release/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy/ Accessed November 2, 2020
- Pfizer’s new phase 1b results of gene therapy in ambulatory boys with duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. Press release. Pfizer. May 15, 2020. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study/default.aspx Accessed November 2, 2020
- Chan, 2019, Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome, Mol Ther, 27
- Letizia, 2019, Engineering AAV vectors to reduce CD8+ T cell responses following intramuscular injection in mice, Mol Ther, 27
- Pfizer presents initial clinical data on phase 1b gene therapy study for duchenne muscular dystrophy (DMD). Press release. Pfizer. June 28, 2019. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd Accessed November 2, 2020
- Solid Biosciences provides SGT-001 program update. Press release. Solid Biosciences. November 12, 2019. https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-sgt-001-program-update Accessed November 2, 2020
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Self-citationTabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
“These two attributes suggest that this class of AAV capsids could lower the dose of virus needed to achieve therapeutic levels of target cell transduction, lessening therapy-related risk for classical activation of complement by capsid/antibody complexes (Muhuri et al., 2021) andmitigating potentially detrimental cons…”
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
“A comprehensive summary of the pharmacological approaches to minimize immune responses against AAV can be found in a recent review 92 .”
BackgroundrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“This situation is further exacerbated by the fact that repeated dosing is challenging due to immune responses against AAV (8).”
BackgroundAddressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
Metadata
- Authors
- Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2021-01-04
- Volume
- 131
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7773343
- OpenAlex
- W3120585537
- Cited by
- 212
- References
- 172
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 59 · 2023: 30 · 2022: 28 · 2021: 11
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (AI067497)
- National Heart, Lung, and Blood Institute (P01HL131471, R01HL097088, UG3HL147367)
- National Institute of Allergy and Infectious Diseases (R01AI132296, R33AI136007, R01AI067497, R01AI128358, R37AI067497, P01AI100263, R01AI141181, U19AI149646, R56AI067497)
- National Institute of Neurological Disorders and Stroke (R01NS076991)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus vectors, recombinant adeno-associated virus, innate immunity, immune evasion, gene therapy vectors, host immune response, in vivo gene therapy, immunogenicity
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Immunity, Innate, Genetic Therapy, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.